Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
AIDS Vaccines | 29 | 2024 | 150 | 8.200 |
Why?
|
HIV Infections | 44 | 2024 | 4946 | 3.580 |
Why?
|
HIV-1 | 19 | 2024 | 1239 | 2.490 |
Why?
|
Pre-Exposure Prophylaxis | 3 | 2021 | 171 | 1.810 |
Why?
|
Adult | 38 | 2024 | 5664 | 1.250 |
Why?
|
Humans | 56 | 2024 | 14077 | 1.230 |
Why?
|
Young Adult | 30 | 2024 | 2357 | 1.200 |
Why?
|
South Africa | 38 | 2023 | 7312 | 1.090 |
Why?
|
Female | 42 | 2024 | 8751 | 1.080 |
Why?
|
Male | 35 | 2024 | 6489 | 1.070 |
Why?
|
HIV Antibodies | 11 | 2024 | 243 | 1.060 |
Why?
|
Altitude | 1 | 2024 | 9 | 0.950 |
Why?
|
Fibrin Fibrinogen Degradation Products | 1 | 2024 | 19 | 0.940 |
Why?
|
Anti-HIV Agents | 4 | 2021 | 1275 | 0.900 |
Why?
|
Adolescent | 24 | 2024 | 2858 | 0.900 |
Why?
|
Circumcision, Male | 3 | 2019 | 97 | 0.850 |
Why?
|
Antibodies, Neutralizing | 5 | 2023 | 285 | 0.850 |
Why?
|
Immunization, Secondary | 4 | 2021 | 62 | 0.810 |
Why?
|
Immunoglobulin G | 5 | 2024 | 220 | 0.790 |
Why?
|
Double-Blind Method | 12 | 2024 | 263 | 0.770 |
Why?
|
Contraception Behavior | 4 | 2011 | 54 | 0.770 |
Why?
|
Neutropenia | 1 | 2021 | 9 | 0.750 |
Why?
|
Adverse Drug Reaction Reporting Systems | 1 | 2021 | 8 | 0.750 |
Why?
|
CD4-Positive T-Lymphocytes | 3 | 2021 | 145 | 0.720 |
Why?
|
Human Immunodeficiency Virus Proteins | 1 | 2020 | 10 | 0.700 |
Why?
|
Condoms | 5 | 2020 | 86 | 0.550 |
Why?
|
Sexual Behavior | 8 | 2023 | 313 | 0.530 |
Why?
|
Adjuvants, Immunologic | 4 | 2024 | 21 | 0.520 |
Why?
|
Polysorbates | 4 | 2024 | 10 | 0.520 |
Why?
|
Squalene | 4 | 2024 | 10 | 0.520 |
Why?
|
HIV Envelope Protein gp120 | 5 | 2024 | 104 | 0.490 |
Why?
|
Genitalia | 1 | 2014 | 8 | 0.490 |
Why?
|
Mucous Membrane | 1 | 2014 | 12 | 0.490 |
Why?
|
Cell Phone | 3 | 2020 | 34 | 0.490 |
Why?
|
Risk Factors | 6 | 2024 | 1431 | 0.490 |
Why?
|
Specimen Handling | 1 | 2014 | 103 | 0.460 |
Why?
|
HIV Seropositivity | 3 | 2023 | 263 | 0.430 |
Why?
|
Fertility | 2 | 2011 | 22 | 0.420 |
Why?
|
Antiretroviral Therapy, Highly Active | 7 | 2017 | 468 | 0.400 |
Why?
|
Immunogenicity, Vaccine | 3 | 2024 | 91 | 0.400 |
Why?
|
Middle Aged | 10 | 2024 | 3425 | 0.400 |
Why?
|
Infectious Disease Transmission, Vertical | 2 | 2012 | 467 | 0.370 |
Why?
|
Menstruation | 2 | 2011 | 10 | 0.370 |
Why?
|
Antibodies, Monoclonal | 3 | 2021 | 137 | 0.370 |
Why?
|
Clinical Trials as Topic | 5 | 2023 | 112 | 0.360 |
Why?
|
Vaccination | 7 | 2020 | 347 | 0.360 |
Why?
|
Menstruation Disturbances | 1 | 2010 | 7 | 0.350 |
Why?
|
Mothers | 1 | 2012 | 190 | 0.350 |
Why?
|
Intention | 2 | 2010 | 23 | 0.350 |
Why?
|
Patient Preference | 1 | 2010 | 22 | 0.350 |
Why?
|
Genetic Vectors | 7 | 2021 | 54 | 0.340 |
Why?
|
Pregnancy Complications, Infectious | 2 | 2012 | 507 | 0.340 |
Why?
|
Antibody Formation | 5 | 2020 | 61 | 0.340 |
Why?
|
Decision Making | 1 | 2009 | 52 | 0.320 |
Why?
|
Anti-Retroviral Agents | 2 | 2016 | 542 | 0.310 |
Why?
|
Healthy Volunteers | 3 | 2024 | 18 | 0.310 |
Why?
|
Focus Groups | 4 | 2020 | 180 | 0.300 |
Why?
|
Incidence | 4 | 2022 | 655 | 0.270 |
Why?
|
Self Report | 4 | 2020 | 111 | 0.270 |
Why?
|
Antibody-Dependent Cell Cytotoxicity | 3 | 2021 | 36 | 0.260 |
Why?
|
Air Travel | 1 | 2024 | 4 | 0.240 |
Why?
|
Oximetry | 1 | 2024 | 6 | 0.240 |
Why?
|
Thrombelastography | 1 | 2024 | 6 | 0.240 |
Why?
|
nef Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 6 | 0.240 |
Why?
|
von Willebrand Factor | 1 | 2024 | 21 | 0.240 |
Why?
|
Anti-Bacterial Agents | 2 | 2019 | 274 | 0.240 |
Why?
|
Alum Compounds | 1 | 2024 | 1 | 0.240 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 20 | 0.230 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 2 | 2014 | 29 | 0.230 |
Why?
|
Thrombosis | 1 | 2024 | 47 | 0.230 |
Why?
|
Follow-Up Studies | 3 | 2021 | 367 | 0.230 |
Why?
|
Data Accuracy | 1 | 2023 | 9 | 0.220 |
Why?
|
Immunization, Passive | 2 | 2020 | 17 | 0.210 |
Why?
|
Adenoviridae | 4 | 2018 | 39 | 0.210 |
Why?
|
Sexual and Gender Minorities | 1 | 2023 | 28 | 0.210 |
Why?
|
Vaginosis, Bacterial | 2 | 2019 | 19 | 0.210 |
Why?
|
Treatment Outcome | 3 | 2020 | 867 | 0.210 |
Why?
|
Communicable Disease Control | 1 | 2023 | 101 | 0.210 |
Why?
|
Enzyme Replacement Therapy | 1 | 2022 | 2 | 0.200 |
Why?
|
Glucosylceramidase | 1 | 2022 | 3 | 0.200 |
Why?
|
Gaucher Disease | 1 | 2022 | 4 | 0.200 |
Why?
|
Vagina | 2 | 2019 | 91 | 0.200 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2023 | 186 | 0.190 |
Why?
|
Health Services Research | 1 | 2021 | 57 | 0.190 |
Why?
|
Immunity, Innate | 1 | 2021 | 10 | 0.190 |
Why?
|
Patient Acceptance of Health Care | 2 | 2015 | 235 | 0.190 |
Why?
|
Pandemics | 1 | 2023 | 280 | 0.190 |
Why?
|
Culture | 2 | 2011 | 21 | 0.180 |
Why?
|
B-Lymphocytes | 1 | 2020 | 33 | 0.180 |
Why?
|
Qualitative Research | 3 | 2012 | 294 | 0.180 |
Why?
|
Socioeconomic Factors | 5 | 2015 | 405 | 0.180 |
Why?
|
Gene Expression Profiling | 1 | 2020 | 41 | 0.180 |
Why?
|
HIV | 3 | 2022 | 380 | 0.180 |
Why?
|
Injection Site Reaction | 1 | 2020 | 3 | 0.180 |
Why?
|
Reminder Systems | 1 | 2020 | 8 | 0.180 |
Why?
|
Health Knowledge, Attitudes, Practice | 3 | 2012 | 247 | 0.180 |
Why?
|
Arthralgia | 1 | 2020 | 4 | 0.180 |
Why?
|
Headache | 1 | 2020 | 7 | 0.180 |
Why?
|
Injections, Intramuscular | 1 | 2020 | 30 | 0.180 |
Why?
|
Sex Factors | 1 | 2021 | 224 | 0.180 |
Why?
|
Interleukin-15 | 1 | 2019 | 1 | 0.170 |
Why?
|
Contraception | 2 | 2011 | 90 | 0.170 |
Why?
|
Administration, Intravaginal | 1 | 2019 | 50 | 0.170 |
Why?
|
Lactobacillus | 1 | 2019 | 7 | 0.170 |
Why?
|
Probiotics | 1 | 2019 | 12 | 0.170 |
Why?
|
Survival Rate | 1 | 2019 | 96 | 0.170 |
Why?
|
Killer Cells, Natural | 1 | 2019 | 50 | 0.170 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2020 | 237 | 0.170 |
Why?
|
Virion | 1 | 2019 | 12 | 0.170 |
Why?
|
Biomedical Research | 1 | 2019 | 48 | 0.170 |
Why?
|
Vaccines, DNA | 2 | 2016 | 10 | 0.170 |
Why?
|
Vaginal Smears | 1 | 2019 | 34 | 0.160 |
Why?
|
HIV Antigens | 4 | 2021 | 26 | 0.160 |
Why?
|
Reproductive Tract Infections | 1 | 2018 | 8 | 0.160 |
Why?
|
Cross-Sectional Studies | 5 | 2017 | 1377 | 0.150 |
Why?
|
Surveys and Questionnaires | 3 | 2019 | 532 | 0.150 |
Why?
|
Antibodies, Viral | 1 | 2020 | 266 | 0.150 |
Why?
|
Adolescent Behavior | 2 | 2015 | 58 | 0.150 |
Why?
|
Pregnancy | 4 | 2012 | 1815 | 0.150 |
Why?
|
Risk-Taking | 4 | 2020 | 119 | 0.150 |
Why?
|
Sexually Transmitted Diseases | 1 | 2018 | 101 | 0.150 |
Why?
|
Immunity, Humoral | 4 | 2019 | 42 | 0.150 |
Why?
|
Pleural Cavity | 1 | 2017 | 7 | 0.140 |
Why?
|
Radiography | 1 | 2017 | 80 | 0.140 |
Why?
|
Genital Diseases, Male | 1 | 2016 | 8 | 0.140 |
Why?
|
Foreskin | 1 | 2016 | 10 | 0.140 |
Why?
|
Penis | 1 | 2016 | 8 | 0.140 |
Why?
|
Sexual Partners | 3 | 2015 | 211 | 0.130 |
Why?
|
Tuberculosis Vaccines | 1 | 2015 | 8 | 0.130 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2017 | 194 | 0.120 |
Why?
|
Interviews as Topic | 3 | 2011 | 190 | 0.120 |
Why?
|
Coinfection | 1 | 2017 | 268 | 0.120 |
Why?
|
Violence | 1 | 2015 | 68 | 0.120 |
Why?
|
Protein Precursors | 1 | 2014 | 22 | 0.120 |
Why?
|
Poverty | 1 | 2015 | 149 | 0.120 |
Why?
|
Reproductive Health Services | 1 | 2015 | 66 | 0.110 |
Why?
|
Immune Tolerance | 1 | 2013 | 22 | 0.110 |
Why?
|
Tuberculosis, Pulmonary | 1 | 2017 | 320 | 0.110 |
Why?
|
Patient Compliance | 2 | 2011 | 120 | 0.110 |
Why?
|
Floxacillin | 1 | 2013 | 6 | 0.110 |
Why?
|
Surgical Wound Infection | 1 | 2013 | 13 | 0.110 |
Why?
|
Primary Health Care | 1 | 2015 | 228 | 0.110 |
Why?
|
Risk Assessment | 3 | 2020 | 217 | 0.110 |
Why?
|
Health Services Accessibility | 2 | 2012 | 265 | 0.100 |
Why?
|
Prejudice | 1 | 2012 | 8 | 0.100 |
Why?
|
Maternal Health Services | 1 | 2012 | 51 | 0.100 |
Why?
|
Canarypox virus | 2 | 2021 | 4 | 0.090 |
Why?
|
Africa South of the Sahara | 3 | 2021 | 328 | 0.090 |
Why?
|
Treatment Failure | 3 | 2021 | 175 | 0.090 |
Why?
|
Reproductive Behavior | 1 | 2010 | 3 | 0.090 |
Why?
|
Cohort Studies | 3 | 2019 | 939 | 0.090 |
Why?
|
Amenorrhea | 1 | 2010 | 9 | 0.090 |
Why?
|
Vaccines, Synthetic | 2 | 2024 | 7 | 0.090 |
Why?
|
Viremia | 1 | 2010 | 66 | 0.090 |
Why?
|
Treatment Refusal | 1 | 2010 | 13 | 0.090 |
Why?
|
Contraceptive Agents, Female | 1 | 2010 | 47 | 0.080 |
Why?
|
Women's Health | 1 | 2009 | 41 | 0.080 |
Why?
|
Safe Sex | 2 | 2019 | 67 | 0.080 |
Why?
|
Ambulatory Care Facilities | 2 | 2020 | 125 | 0.080 |
Why?
|
Papillomaviridae | 1 | 2008 | 33 | 0.080 |
Why?
|
Drug Resistance, Viral | 1 | 2010 | 268 | 0.080 |
Why?
|
DNA, Viral | 1 | 2008 | 165 | 0.070 |
Why?
|
Risk | 2 | 2021 | 87 | 0.070 |
Why?
|
Papillomavirus Infections | 1 | 2008 | 72 | 0.070 |
Why?
|
Interferon-gamma | 2 | 2019 | 39 | 0.070 |
Why?
|
CD4 Lymphocyte Count | 3 | 2017 | 654 | 0.070 |
Why?
|
Infant, Newborn | 1 | 2012 | 1410 | 0.070 |
Why?
|
Immunity, Cellular | 2 | 2018 | 25 | 0.070 |
Why?
|
Prospective Studies | 2 | 2019 | 1131 | 0.060 |
Why?
|
Genotype | 2 | 2022 | 430 | 0.060 |
Why?
|
Substance-Related Disorders | 2 | 2015 | 49 | 0.060 |
Why?
|
Viral Vaccines | 1 | 2024 | 21 | 0.060 |
Why?
|
Proportional Hazards Models | 2 | 2015 | 163 | 0.060 |
Why?
|
Vaccines, Combined | 1 | 2024 | 34 | 0.060 |
Why?
|
Immunoglobulin A | 1 | 2024 | 39 | 0.060 |
Why?
|
Child | 2 | 2022 | 2180 | 0.050 |
Why?
|
Disease Progression | 2 | 2017 | 154 | 0.050 |
Why?
|
Infant | 2 | 2022 | 2145 | 0.050 |
Why?
|
Homosexuality, Male | 1 | 2023 | 48 | 0.050 |
Why?
|
Demography | 2 | 2014 | 105 | 0.050 |
Why?
|
Community Participation | 1 | 2022 | 42 | 0.050 |
Why?
|
Multivariate Analysis | 2 | 2014 | 171 | 0.050 |
Why?
|
Splenectomy | 1 | 2022 | 3 | 0.050 |
Why?
|
Thrombocytopenia | 1 | 2022 | 11 | 0.050 |
Why?
|
Anemia | 1 | 2022 | 41 | 0.050 |
Why?
|
Registries | 1 | 2022 | 89 | 0.050 |
Why?
|
Americas | 1 | 2021 | 10 | 0.050 |
Why?
|
Proof of Concept Study | 1 | 2021 | 13 | 0.050 |
Why?
|
Europe | 1 | 2021 | 53 | 0.050 |
Why?
|
Leukocytes, Mononuclear | 1 | 2021 | 60 | 0.050 |
Why?
|
Vaccinia virus | 1 | 2020 | 2 | 0.050 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2020 | 6 | 0.050 |
Why?
|
Half-Life | 1 | 2020 | 21 | 0.050 |
Why?
|
Longitudinal Studies | 1 | 2022 | 409 | 0.050 |
Why?
|
Lymphocyte Activation | 1 | 2020 | 40 | 0.050 |
Why?
|
Gene Expression Regulation | 1 | 2020 | 40 | 0.050 |
Why?
|
Linear Models | 1 | 2020 | 82 | 0.040 |
Why?
|
Signal Transduction | 1 | 2020 | 33 | 0.040 |
Why?
|
Plasmids | 1 | 2020 | 23 | 0.040 |
Why?
|
Retrospective Studies | 2 | 2013 | 767 | 0.040 |
Why?
|
DNA | 1 | 2020 | 73 | 0.040 |
Why?
|
Granzymes | 1 | 2019 | 1 | 0.040 |
Why?
|
Text Messaging | 1 | 2020 | 25 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2020 | 30 | 0.040 |
Why?
|
Cefixime | 1 | 2019 | 2 | 0.040 |
Why?
|
Doxycycline | 1 | 2019 | 3 | 0.040 |
Why?
|
Metronidazole | 1 | 2019 | 4 | 0.040 |
Why?
|
CD40 Ligand | 1 | 2019 | 4 | 0.040 |
Why?
|
Thailand | 1 | 2019 | 24 | 0.040 |
Why?
|
Interleukin-2 | 1 | 2019 | 22 | 0.040 |
Why?
|
Phagocytosis | 1 | 2019 | 15 | 0.040 |
Why?
|
Principal Component Analysis | 1 | 2019 | 20 | 0.040 |
Why?
|
Placebos | 1 | 2019 | 44 | 0.040 |
Why?
|
Glycogen | 1 | 2019 | 3 | 0.040 |
Why?
|
Epitopes | 1 | 2020 | 97 | 0.040 |
Why?
|
Coitus | 1 | 2019 | 15 | 0.040 |
Why?
|
Viral Load | 2 | 2016 | 808 | 0.040 |
Why?
|
T-Lymphocytes | 1 | 2019 | 59 | 0.040 |
Why?
|
Neutralization Tests | 1 | 2019 | 106 | 0.040 |
Why?
|
Unsafe Sex | 1 | 2019 | 45 | 0.040 |
Why?
|
Pilot Projects | 1 | 2019 | 168 | 0.040 |
Why?
|
Trichomonas Vaginitis | 1 | 2018 | 4 | 0.040 |
Why?
|
Trichomonas Infections | 1 | 2018 | 5 | 0.040 |
Why?
|
Herpes Simplex | 1 | 2018 | 7 | 0.040 |
Why?
|
Syphilis | 1 | 2018 | 14 | 0.040 |
Why?
|
Chlamydia Infections | 1 | 2018 | 17 | 0.040 |
Why?
|
Gonorrhea | 1 | 2018 | 20 | 0.040 |
Why?
|
Candidiasis | 1 | 2018 | 15 | 0.040 |
Why?
|
Dizziness | 1 | 2018 | 2 | 0.040 |
Why?
|
Back Pain | 1 | 2018 | 4 | 0.040 |
Why?
|
Macaca mulatta | 1 | 2018 | 14 | 0.040 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 10 | 0.040 |
Why?
|
Abdominal Pain | 1 | 2018 | 7 | 0.040 |
Why?
|
Africa, Southern | 1 | 2018 | 89 | 0.040 |
Why?
|
Fatigue | 1 | 2018 | 20 | 0.040 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 124 | 0.040 |
Why?
|
Feasibility Studies | 1 | 2018 | 95 | 0.040 |
Why?
|
Data Collection | 1 | 2018 | 86 | 0.040 |
Why?
|
Diarrhea | 1 | 2018 | 76 | 0.040 |
Why?
|
Aged | 1 | 2022 | 1650 | 0.040 |
Why?
|
Child, Preschool | 1 | 2022 | 1675 | 0.040 |
Why?
|
Antibiotics, Antitubercular | 1 | 2017 | 47 | 0.030 |
Why?
|
Predictive Value of Tests | 1 | 2017 | 183 | 0.030 |
Why?
|
tat Gene Products, Human Immunodeficiency Virus | 1 | 2016 | 2 | 0.030 |
Why?
|
Anti-Infective Agents, Local | 1 | 2016 | 16 | 0.030 |
Why?
|
Africa, Eastern | 1 | 2016 | 16 | 0.030 |
Why?
|
Pediatrics | 1 | 2016 | 16 | 0.030 |
Why?
|
United States | 1 | 2016 | 129 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 150 | 0.030 |
Why?
|
Acyltransferases | 1 | 2015 | 4 | 0.030 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2015 | 11 | 0.030 |
Why?
|
BCG Vaccine | 1 | 2015 | 20 | 0.030 |
Why?
|
Antigens, Bacterial | 1 | 2015 | 32 | 0.030 |
Why?
|
CD8-Positive T-Lymphocytes | 1 | 2015 | 43 | 0.030 |
Why?
|
Animals | 1 | 2018 | 1063 | 0.030 |
Why?
|
Sex Offenses | 1 | 2015 | 29 | 0.030 |
Why?
|
Enzyme-Linked Immunospot Assay | 1 | 2014 | 10 | 0.030 |
Why?
|
Antibodies, Bacterial | 1 | 2015 | 149 | 0.030 |
Why?
|
Depression | 1 | 2015 | 117 | 0.030 |
Why?
|
Administration, Oral | 1 | 2013 | 113 | 0.030 |
Why?
|
Cross-Cultural Comparison | 1 | 2011 | 16 | 0.020 |
Why?
|
Brazil | 1 | 2011 | 43 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 1 | 2011 | 103 | 0.020 |
Why?
|
Epidemiologic Methods | 1 | 2010 | 25 | 0.020 |
Why?
|
Kenya | 1 | 2011 | 173 | 0.020 |
Why?
|
Logistic Models | 1 | 2010 | 252 | 0.020 |
Why?
|
Tuberculosis | 1 | 2015 | 530 | 0.020 |
Why?
|
Prevalence | 1 | 2010 | 1149 | 0.020 |
Why?
|